Basic HTML Version
39
Mariusz Kwarciany i wsp.,
Leki przeciwpłytkowe w udarze mózgu
www.chsin.viamedica.pl
PIŚMIENNICTWO
1.
DonnanG.A.,FisherM.,MacleodM.,DavisS.M.Stroke.
Lancet
2008;371:1612–1623.
2.
European Stroke Organisation (ESO) Executive Committee; ESOWriting Com-
mittee. Guidelines for management of ischaemic stroke and transient ischaemic
attack 2008.
Cerebrovasc. Dis.
2008; 25: 457–507.
3.
Ridker P.M., Cook N.R., Lee I.M. i wsp. A randomized trial of low-dose aspirin in
theprimarypreventionof cardiovascular disease inwomen.
N. Engl. J.Med.
2005;
352: 1293–1304.
4.
Bartolucci A., Howard G. Meta-analysis of data from the six primary prevention
trias of cardiovascular events using aspirin.
Am. J. Cardiol.
2006; 98: 746–750.
5.
Berger J., Roncaglioni M., Avanzini F., Pangrazzi I., Tognoni G., Brown D. Aspi-
rin for the primary prevention of cardiovascular events inwomen andmen: a sex-
specificmeta-analysis of randomizedcontrolled trials.
JAMA
2006; 295: 306–313.
6.
Bhatt D., Fox K., HackeW. i wsp. Clopidogrel and aspirin versus aspirin alone for
thepreventionof atherothromboticevents.
N. Engl. J.Med.
2006; 354: 1706–1717.
7.
Hobson R. 2nd, Krupski W., Weiss D. Influence of aspirin in the management of
asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymp-
tomatic Carotid Stenosis.
J. Vasc. Surg.
1993; 17: 257–263.
8.
Engelter S., Lyrer P. Antiplatelet therapy for preventing stroke and other vascu-
lar events after carotid endarterectomy.
Cochrane Database Syst. Rev.
2003:
CD001458.
9.
Goldstein L.B., Bushnell C.D., Adams R.J. i wsp. Guidelines for the Primary Pre-
vention of Stroke: a guideline for healthcare professionals from the American
Heart Association/American Stroke Association.
Stroke
2011; 42: 517–584.
10. ACTIVE Investigators, Connolly S.J., Pogue J., Hart R.G. i wsp. Effect of clopi-
dogrel added to aspirin in patients with atrial fibrillation.
N. Engl. J. Med
. 2009;
360: 2066–2078.
11. Connolly S.J., Ezekowitz M.D., Yusuf S. i wsp. RE-LY Steering Committee and
Investigators. Dabigatran versuswarfarin in patientswith atrial fibrillation.
N. Engl.
J. Med.
2009; 361: 1139–1151.
12. Manesh R., Patel M.D., Kenneth W. i wsp. Rivaroxaban versus warfarin in non-
valvular atrial fibrillation.
N. Engl. J. Med.
2011; 365: 883–891.
13. Stuart J., Connolly S.J., Eikelboom J. i wsp. Apixaban in Patients with Atrial Fi-
brillation.
N. Engl. J. Med.
2011; 364: 806–817.
14. Granger C.B., Alexander J.H., McMurray J.J. i wsp. Apixaban versus warfarin in
patients with atrial fibrillation.
N. Engl. J. Med.
2011; 365: 981–992.
15. International-Stroke-Trial-Collaborative-Group: The International Stroke Trial
(IST): a randomised trial if aspirin, subcutaneous heparin, both, or neither among
19,435 patients with acute ischaemic stroke.
Lancet
1997; 349: 1569–1581.
16. CAST-Collaborative-Group:CAST: randomisedplacebo-controlledtrialofearlyaspirin
use in 20,000 patients with acute ischeaemic stroke.
Lancet
1997; 349: 1641–1649.
17. AbESTT Investigators. Emergency administration of abciximab for treatment of
patients with acute ischemic stroke: results of a randomized phase 2 trial.
Stro-
ke
2005; 36: 880–890.
18. Adams H.P. Jr, EffronM.B., Torner J. i wsp. Emergency administration of abcixi-
mab for treatment of patients with acute ischemic stroke: results of an interna-
tional phase III trial. Abciximab in Emergency Treatment of Stroke Trial (AbESTT-
-II).
Stroke
2008; 39: 87–99.
19. Siebler M., Hennerici M.G., Schneider D. i wsp. Safety of Tirofiban in Acute Ische-
mic Stroke: The SaTIS Trial.
Stroke
2011; 42: 2388–2392.
20. Antithrombotic Trialists’ Collaboration. Collaborativemeta-analysis of randomi-
zed trials of antiplatelet therapy for prevention of death, myocardial infarction,
and stroke in high risk patients.
Br. Med. J.
2002; 324: 71–86.
21. Algra A., van Gijn J. Aspirin at any dose above 30mg offers only modest protec-
tion after cerebral ischaemia.
J. Neurol. Neurosurg. Psychiatry
1996; 60: 197–199.
22. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg
vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic
stroke.
N. Engl. J. Med.
1991; 325: 1261–1266.
23. Farrell B., Godwin J., RichardsS.,WarlowC. TheUnitedKingdom transient ischa-
emic attack (UK-TIA) aspirin trial: final results.
J. Neurol. Neurosurg. Psychiatry
1991; 54: 1044–1054.
24. Campbell C., Smyth S., Montalescot G., Steinhubl S. Aspirin dose for the pre-
vention of cardiovascular disease: a systematic review.
JAMA
2007; 297: 2018–
–2024.
25. Chimowitz M., Lynn M., Howlett-Smith H. i wsp. Comparison of warfarin and
aspirin for symptomatic intracranial arterial stenosis.
N. Engl. J. Med.
2005; 352:
1305–1316.
26. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus
aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–
–1339.
27. Costa J., FerroJ.M.,Matias-Guiu J., Alvarez-Sabin J., TorresF. Triflusal for preven-
ting serious vascular events in people at high risk.
CochraneDatabase Syst. Rev.
2005: CD004296.
28. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European
Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secon-
dary prevention of stroke.
J. Neurol. Sci
. 1996; 143: 1–13.
29. Halkes P., van Gijn J., Kappelle L., Koudstaal P., Algra A. Aspirin plus dipyrida-
mole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): ran-
domized controlled trial.
Lancet
2006; 367: 1665–1673.
30. ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after
cerebral ischemia of arterial origin (ESPRIT): a randomized controlled trial.
Lan-
cet Neurol.
2007; 6: 115–122.
31. SaccoR.L.,DienerH.C., Yusuf S. i wsp. Aspirinandextended-releasedipyridamole
versus clopidogrel for recurrent stroke.
N. Engl. J. Med.
2008; 359: 1238–1251.
32. Diener H., Bogousslavsky J., Brass L. i wsp. Aspirin and clopidogrel compared
with clopidogrel alone after recent ischaemic stroke or transient ischaemic at-
tack in high-risk patients (MATCH): randomised, double-blind, placebo-control-
led trial.
Lancet
2004; 364: 331–337.
33. Jakubowski J.A., Winters K.J., Naganuma H., Wallentin L. Prasugrel: a novel
thienopyridine antiplatelet agent. A review of preclinical and clinical studies and
the mechanistic basis for its distinct antiplatelet profile.
Cardiovasc. Drug Rev.
2007; 25: 357–374.
34. Brandt J.T., Payne C.D., Wiviott S.D. i wsp. A comparison of prasugrel and clo-
pidogrel loading doses on platelet function: magnitude of platelet inhibition is
related to active metabolite formation
. Am. Heart J.
2007; 153: e69–e16.
35. Wiviott S.D., Braunwald E., McCabe C.H. i wsp. Prasugrel versus clopidogrel in
patientswith acute coronary syndromes.
N. Engl. J. Med.
2007; 357: 2001–2015.
36. Storey R.F., Husted S., Harrington R.A. i wsp. Inhibition of platelet aggregation
by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopi-
dogrel in patients with acute coronary syndromes.
J. Am. Coll. Cardiol.
2007; 50:
1852–1856.
37. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., Peters G.
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12
antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind
comparison to clopidogrel with aspirin.
Eur. Heart J.
2006; 27: 1038–1047.
38. Wallentin L., Becker R.C., Budaj A. i wsp. Ticagrelor versus Clopidogrel in Pa-
tients with Acute Coronary Syndromes.
N. Engl. J. Med.
2009; 361: 1045–1057.